Propanc Biopharma, Inc. (PPCB): Total Liabilities
$5.73M
As of 2025-06-30
$3.51M
As of 2026-03-31
+22.6%
3-year compound annual growth
+8.9%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-06-30 | $5.73M | +48.7% | 2025-09-29, Balance as of period end |
| 2024-06-30 | $3.85M | +21.2% | 2025-09-29, Balance as of period end |
| 2023-06-30 | $3.18M | +2.3% | 2024-09-30, Balance as of period end |
| 2022-06-30 | $3.11M | +0.8% | 2023-09-28, Balance as of period end |
| 2021-06-30 | $3.08M | -17.6% | 2022-09-28, Balance as of period end |
| 2020-06-30 | $3.74M | -15.1% | 2021-09-28, Balance as of period end |
| 2019-06-30 | $4.40M | n/a | 2020-10-01, Balance as of period end |
| No annual figure between 2012-06-30 and 2019-06-30. | |||
| 2012-06-30 | $584.2K | +90.4% | 2012-10-15, Balance as of period end |
| 2011-06-30 | $306.8K | n/a | 2012-10-15, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Propanc Biopharma, Inc. (PPCB) | 2025-06-30 | $5.73M | +48.7% |
| Galectin Therapeutics Inc (GALT) | 2025-12-31 | $145.73M | +20.9% |
| Lftd Partners Inc. (LIFD) | 2025-12-31 | $6.64M | -34.4% |
| Marker Therapeutics, Inc. (MRKR) | 2025-12-31 | $2.27M | -34.4% |
| Genelux Corp (GNLX) | 2025-12-31 | $7.48M | -11.4% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $89.71M | -0.6% |
| Quoin Pharmaceuticals Ltd. (QNRX) | 2025-12-31 | $7.27M | +11.8% |
| Nexentis Technologies Inc. (NXTS) | 2025-12-31 | $4.67M | +424.1% |
| Incannex Healthcare Inc. (IXHL) | 2025-06-30 | $7.06M | +21.1% |
Compare PPCB, GALT, LIFD, MRKR side by side · Screen every company in Pharmaceutical Preparations ↗